Kantar vs ZoomRx: Why Brand Equity Tracking and Pharma Launch Tracking Are Different Problems

Kantar is one of the most established names in brand research, with a pharma panel covering 2 million healthcare professionals across 56 countries and decades of proven methodology in consumer pharma and multinational brand equity monitoring. What makes this comparison worth having is that Kantar has published extensively on the structural limitations of traditional tracking: data silos, lack of agility, and "set it and forget it" mindsets. Those are exactly the problems ZoomRx's architecture was built to solve. So the question for any brand team evaluating Kantar is straightforward: would you rather work with a firm that acknowledges tracking's known limitations, or one that has engineered them out of the model?

What Kantar Does Well

Kantar's consumer brand tracking methodology is genuinely world-class. For multinational pharmaceutical companies needing consistent brand health metrics across 15+ markets, their global infrastructure is valuable. Their BrandDynamics tool delivers daily brand performance data. Their Blueprint for Brand Growth has been adapted for pharma. And for OTC and consumer health brands, Kantar's equity constructs translate well to purchase decision dynamics.

Where the Methodology Mismatch Appears for Prescription Drug Launch Tracking

Brand equity frameworks are not ATU frameworks

Kantar's core methodology tracks brand salience, differentiation, and consumer affinity — constructs designed to explain how brand identity drives consumer purchase behavior. These are the right questions for consumer goods and OTC pharma.

For prescription drugs, the relevant questions are categorically different: which physicians are aware of the drug, which have prescribed it, which have been exposed to promotion and what they recall, which are hesitant and why, and what patient types are driving trial. These are ATU and PET questions. Kantar's Blueprint for Brand Growth, adapted from FMCG, is a different intellectual model than the ATU/PET/PCA construct that drives HCP-focused pharma launch intelligence. Applying the wrong framework produces misaligned benchmarks and misframed strategic recommendations.

Kantar acknowledges tracking's problems — but hasn't architecturally solved them

Kantar has published research documenting the structural weaknesses of traditional tracking approaches: data silos, agility gaps, and "set it and forget it" program design. These are the exact structural problems ZoomRx's unified screener, proprietary panel, voice-first methodology, and live AI platform were built to eliminate.

A firm that documents the problem and a firm that has architecturally removed it are in different positions for a launch brand that cannot afford to manage around known limitations.

Separate research modules — no traceable chain at the respondent level

Kantar runs pharma research modules as separate programs — each with its own screener, physician sample, and timeline. ATU research, promotional effectiveness, and patient chart studies are fielded independently, with synthesis at reporting.

ZoomRx's unified screener enrolls the same physicians across all modules. The physician providing chart data is the same physician who answered the awareness and promotional recall questions — in the same wave. The connection between promotion, perception, and prescribing is measured, not inferred.

No proprietary pharma-specific launch benchmark database

Kantar's benchmarks draw primarily from brand equity norms across industries, including pharma. Their launch readiness benchmarking uses broad brand health data. What they do not have is a database of primary research benchmarks from actual pharmaceutical launches — ATU awareness trajectories, PET recall rates, trial rate comparisons — matched by therapeutic area and time point.

ZoomRx's benchmark library covers 700M+ data points across 500+ pharmaceutical launches. The specificity of those benchmarks is a direct result of running launch tracking as the core product for years.

Global standardization works against a focused US launch

Kantar's global infrastructure is an asset for multinational programs. For a US-focused launch brand that needs fast, specialized, continuous primary research, that infrastructure adds standardization layers: research design must accommodate global framework requirements, timelines are shaped by coordination processes, and attention is distributed across a large, diversified portfolio. ZoomRx's proprietary panel of 60,000+ verified US physicians enables follow-up in days, without global overhead.

No voice-first capability and no live AI query tool

Kantar has invested in brand tracking technology — dashboards, automated reporting, and connected data frameworks. These are useful for accessing completed data. They do not include ZoomRx's voice-first methodology (real-time audio responses from physicians embedded within the quantitative tracking survey) or ZoomRx Answers (a natural language interface that lets brand teams query live respondent data within minutes of a wave closing). ZoomRx's researchers are pharma-only, launch-specialized, and operationally obsessed — that is the kind of depth that does not exist in a firm calibrated for a diversified global client base.

Kantar vs ZoomRx: Side-by-Side

The Question That Decides It

Ask any vendor: "Show me how promotional exposure in your research connects to physician perception, which connects to prescribing intent, which connects to what your chart audit data shows — all from the same respondent pool, in the same data environment."

Kantar will show you brand tracking dashboards that aggregate survey data from separately recruited samples, built on a brand equity framework designed for consumer decision-making. ZoomRx will show you a platform where you can pull up that physician's promotional recall score, their prescribing intent response, their chart audit summary, and the voice clip of them explaining why they haven't prescribed yet — all from the same person, in one place, available today.

That is the difference between adapted brand research and purpose-built pharma launch intelligence.

Find out whether your launch tracking methodology is built for HCP prescribing decisions — and how your metrics compare against primary research benchmarks from 500+ pharma launches.

Frequently Asked Questions